Anti-phosphospecific JNK/SAPK (Thr183/Tyr185), p38 (Thr180/Tyr182), Elk1 (Ser383), ATF2 (Thr71), c-Jun (Ser63), AKT (Ser473), GSK3β (Ser9), anti-Elk1, ATF2, c-Jun, and AKT antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-phosphospecific ERK1/2, tyrosine (PY99), anti-ERK1/2, JNK/SAPK, p38, proliferating cell nuclear antigen (PCNA), and c-Met antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). GSK3β antibody was purchased from Transduction Laboratories (Palo Alto, CA), cyclin D1 antibody from PD Biosciences-Pharmingen (Palo Alto, CA), and actin antibody from Sigma-Aldrich (St. Louis, MO). Human c-Met antibody for neutralization and c-hHGF antibody were purchased from R&D Systems (Minneapolis, MN). Recombinant HGF was purchased from R&D Systems. The MAPK inhibitors U0126, SP600125, SB202190, and the PI3K inhibitor wortmannin were obtained from Calbiochem (La Jolla, CA).